PDS Biotechnology Corp: Nant Capital, LLC amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Nant Capital, LLC filed an amended Schedule 13D with the SEC (accession 0001193125-26-456632) covering its stake in PDS Biotechnology Corp. The amendment updates the investor's previously reported position in the clinical-stage immunotherapy developer. The filing does not disclose a change in share count or ownership percentage in the headline. The update matters because Schedule 13D amendments signal shifts in activist or strategic holders' intent at portfolio companies. Investors will watch for further filings or public statements from Nant Capital clarifying its plans for the PDS Biotechnology position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Nant Capital, LLC, PDS Biotechnology Corp